

Special Issue

Platelets in Health and Disease: From Molecular Mechanisms to Therapeutic Potential

Message from the Guest Editor

Recently, platelets have also been implicated in various tissue remodeling processes, such as apoptosis, immune patrolling, and adaptive immunity. They play a critical role in the immediate response to vascular injury by promoting vascular inflammation and immunomodulation. These discoveries have led to a broader understanding of platelets as immune cells. Platelets continue to captivate both clinicians and basic scientists as new interactions between platelets, their precursor cells (megakaryocytes), and novel immune cell populations are uncovered. Emerging roles of platelets in disease mechanisms are being identified, and they are increasingly recognized as valuable targets for therapeutic interventions and as potential biomarkers. Contributions to this Special Issue, "Platelets in Health and Disease: From Molecular Mechanisms to Therapeutic Potential", should focus on recent advancements that reinforce the concept of platelets as crucial mediators of vascular immunity, integral components of the immune system, promising therapeutic targets, or biomarkers, particularly in relation to their lipidome, transcriptome, or proteome.

Guest Editor

Dr. Henry Nording

1. Cardioimmunology Group, Medical Clinic II, University Heart Center Luebeck, Luebeck, Germany
2. DZHK (German Research Centre for Cardiovascular Research), Partner Site Hamburg/Lübeck/Kiel, 23562 Lübeck, Germany

Deadline for manuscript submissions

31 August 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/215441

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).